Compare Recursion Pharmaceuticals Inc (RXRX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tidewater Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Tidewater Inc trades at $78.18 (market cap $3.75B). The key difference: Tidewater Inc is far larger — about 2.5× Recursion Pharmaceuticals Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TDW | |
|---|---|---|
Market Cap | $1.53B | $3.75B |
Sector | Health | Utilities |
52-Week High | $6.79 | $91.12 |
52-Week Low | $2.84 | $47.29 |
Enterprise Value | $946.50M | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical outlook supported by moving averages but recent earnings misses in Q1 and Q4 2026. The company maintains strong profitability with a 22.16% net margin and a P/E of 12.79, while news highlights an acquisition by FTAI Infrastructure (GlobeNewsWire, June 29, 2026).
Outlook is mixed: valuation appears reasonable with solid cash flow, but earnings volatility and sector headwinds pose risks. Analyst consensus leans hold (61.54%), suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
